Search

The Department of Plant Pathology and Environmental Microbiology is seeking a Research Technologist to perform a primary role in developing biological control cocktails that could be used to suppress bacterial blotch of mushroom in organic

Dr. Jeffrey Turner and Dr. Daniele Provenzano The successful applicant will conduct research related to bacterial genomics, pathogenesis and molecular biology. The project entails dissecting the contribution of a novel bacteriophage in modu

A Research Fellow is required within the School of Life Sciences to support a new project in collaboration with partners in China entitled ‘Novel biocontrol to combat Clostridium perfringens in poultry flocks’. Ideally you will have a stron

Dr. Jeffrey Turner and Dr. Daniele Provenzano The successful applicant will conduct research related to bacterial genomics, pathogenesis and molecular biology. The project entails dissecting the contribution of a novel bacteriophage in modu

The Department of Plant Pathology and Environmental Microbiology is seeking a Research Technologist to perform a primary role in developing biological control cocktails that could be used to suppress bacterial blotch of mushroom in organic

Could phages help explain the mysteriously healing qualities of India's Ganges river? If you're looking to learn about some interesting phage-related history (and mystery), you may like this excerpt of the new book "Ganges: The Many Pasts O

Conflicting status. Checked 2026-10-03. This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool. A Phase 1/2a Double-Blind, Randomized,

Completed. Checked 2026-10-03. Study LBx-1001 is a multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LBP-EC01 in patients with indwelling urinary catheters, or

Terminated. Checked 2026-10-03. This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with urinary tract infections. A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of T

Completed. Checked 2026-10-03. Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic ca

Unavailable. Checked 2026-10-03. Phage Treatment in Covid-19 Patients with Bacterial Co-Infections Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii,

Recruiting. Checked 2026-10-03. This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject. Phage Safety Cohort

Completed. Checked 2026-10-03. This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the s

Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. Randomized Open Label, Parallel Group, Controlled Study to Evaluate the Safety and Surgery Spari

Status unconfirmed. Checked 2026-10-03. This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aerugino

Terminated. Checked 2026-10-03. This is a phase 2b randomized trial designed to evaluate bacteriophage therapy in subjects with diabetic foot osteomyelitis. Phase 2b Randomized, Parallel, Double-blind, Placebo-Controlled, Repeat Dose, Multi

Active, not recruiting. Checked 2026-10-03. The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella ch

Completed. Checked 2026-10-03. Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic T

Withdrawn. Checked 2026-10-03. This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (P

Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Eff